New trends in maintenance immunosuppression

Annales Chirurgiae et Gynaecologiae

Volumn 86, Issue 2, 1997, Pages 164-170

  Isoniemi, H ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Immunosuppressive drugs; Maintenance immunosuppression; Mycophenolate mofetil; New immunosuppressive drugs; Rapamycin; Tacrolimus

Indexed keywords

AZATHIOPRINE; BREQUINAR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; CYCLOSPORIN A [8 DEXTRO O (2 HYDROXYETHYL)SERINE]; CYCLOSPORIN DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; LYMPHOCYTE ANTIBODY; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

CLINICAL TRIAL; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MICROEMULSION; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; REVIEW;

DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS;

EID: 0030700697     PISSN: 03559521     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Sweeney MJ, Hoffman DH, Esterman MA: Metabolism and biochemistry of mycophenolic acid. Cancer Res 32: 1803-1809, 1972
2. Franklin TJ, Cook JM: The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 113: 515-524, 1969
3. Sollinger HW, Eugei EM, Allison AC: RS-61443 mechanism of action, experimental and early clinical results. Clin Transplant 6: 523-526, 1991
4. Sollinger HW: From mice to man: the preclinical history of mycophenolate mofetil. Clin Transplant 10: 85-92, 1996
5. Allison AC, Hovi T, Watts RWE, Webster ABD: Immunological observations on patients with Lesch-Nyhan syndrome and the role of de novo purine synthesis in lymphocyte transformation. Lancet 2: 1179, 1975
6. Allison AC, Eugei EM: Mycophenolate Mofetil (RS-61443) mode of action and effects on graft rejection. In: Immunosuppressive drugs, developments in Anti-Rejection Therapy. Eds A.W. Thompson and T.F. Starzl. Edward Arnold, New York, 1994, p. 141-159
7. Carr SF, Papp E, Wu JC, Natsemuda Y: Characterisation of human type I and type II IMP dehydrogenases. J Biol Chem 268: 27286-27290, 1993
8. Chen SF, Perrella FW, Behrens DL, Papp LM: The inhibition of dihyroorotate dehydrogenase activity by brequinar sodium. Cancer Res 52: 3521-3527, 1992
9. Nair RV, Cao W, Morris RE: Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. Immunol Lett 48: 77-80, 1995
10. Xu X, Williams JW, Gong H, Finnegan A, Chong AS: Two activites of the immunosuppressive metabolite of leflunimide, A77 17268. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol 52: 527-534, 1996
11. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807-815, 1991
12. Henderson DJ, Naya I, Bundick RV, Smith GM, Schmidt JA: Comparison of the effects of FK-506, cyclosporine and rapamycin on II-2 production. Immunology 73: 316-321, 1991
13. Holt DW, Mueller EA, Kovarik JM, van Bree JB, Kutz K: The pharmacokinetics of Sandimmun neoral: a new formulation of cyclosporine. Transplant Proc 26: 2935-2939, 1994
14. Kahan BD, Dunn J, Fitts C, van Buren D, Wombolt D, Pollak R, Carson R, Alexander JW, Choc M, Wong R, Hwang DS: Reduced inter- and intrasubject variability in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals or high-fat meals. Transplantation 59: 505-511, 1995
15. Kovarik JM, Mueller EA, van Bree JB, Fluckiger GS, Lang H, Schmidt B, Boesken WH, Lison AE, Kutz K: Cyclosporine pharmacokinetics and variability from a microemulsion formulation - a multicentre investigation in kidney transplant patients. Transplantation 58: 658-663, 1994
16. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Koshaka M, Aoki H, Imanaka H: FK-506, a novel immunosuppressant isolated from a steptomyces. I. Fermentation, osolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 40: 1249-1255, 1987
17. Chung J, Kuo CJ, Crabtree GR, Blenis J: Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kD S6 protein kinases. Cell 69: 1227-1236, 1992
18. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029-1037, 1996
19. Sollinger HW for the US renal transplant mycophenolate mofetil study group: Mycophenolate mofetil for the prevention of acute rejection in renal allograft recipients. Transplantation 60: 225-232, 1995
20. European mycophenolate mofetil cooperative study: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345: 1321-1325, 1995
21. The Myciphenolate Mofetil Renal Refractory Rejection Study Group: Rescue therapy with mycophenolate mofetil. Clin Transplant 10: 131-135, 1996
22. Moore RH, The UK Neoral Study Group: UK multicentre study to assess the safety and tolerability of Neoral in stable renal transplant patients. Transpl Int 9 (Suppl 1): 311-313, 1996
23. Hoppu K, Jalanko H, Laine J, Holmberg C: Comparison of conventional oral cyclosporine and cyclosporine microemulsion formulation in children with a liver transplant. A pharmacokinetic and clinical study. Transplantation 62: 66-71, 1996
24. Hoitsma AJ: The IMM 125 Multicentre study group. Comparison of Sandimmun with a new cyclosporine derivative (IMM 125) in renal transplant patients with stable renal function. Transplant Int 9 (Suppl): 314-317, 1996
25. European FK506 multicenter liver study group: Randomised trial comparing tacrolimus (FK506) and cyclosporin in of liver allograft rejection. Lancet 344: 423-428, 1994
26. U.S. multicenter FK506 liver study group: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331: 1110-1115, 1994
27. Jonas S, Bechstein WO, Lemmens H-P, Kling N, Grauhan O, Lobeck H, Neuhaus P: Conversion to tacrolimus after liver transplantation. Transpl Int 9: 23-31, 1996